Article

Efficacy and Safety Are Key Factors When Selecting Breast Cancer Treatment

The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to one expert.

The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to Dr. Sara Hurvitz.

CURE® recently spoke with Hurvitz, an associate professor of medicine at the University of California, Los Angeles, who walked through different scenarios in which safety and efficacy of each option may be given more weight depending on a patient’s situation, ultimately leading to a treatment decision that is most beneficial to the patient.

Transcript:

Both efficacy and safety of a given therapeutic are equally important considerations when deciding which therapy to go on.

In some situations, the safety profile is going to be more critical. For example, when a patient requires therapy to be given for an extended period of time, we have to consider how that drug’s safety profile and side effect profile is going to allow the patient to interact in her life.

In the early-stage setting, where we’re giving, for example, chemotherapy for three to four months, the safety profile is going to be a little worse, but we are trying to improve the patient’s odds for a cure. So, we are more willing to take on that toxicity profile.

That said, in every situation, the patient needs to be an active participant who is engaged with the clinician in making the decision regarding what type of therapy he or she will decide to take.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Related Content